Osimertinib, which has the best efficacy and most favorable side-effect profile of all EGFR inhibitors, is currently the drug for first-line treatment of EGFR mutant NSCLC, particularly in patients with BM [31]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.